Price movement over the last 24 hours
ADMA Biologics Inc vs Flux Power Holdings Inc — how do they compare? ADMA Biologics Inc trades at $9.21 (market cap $2.13B), while Flux Power Holdings Inc trades at $0.73 (market cap $16.02M). The key difference: ADMA Biologics Inc is far larger — about 133× Flux Power Holdings Inc's market cap, and ADMA Biologics Inc is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | FLUX | |
|---|---|---|
Market Cap | $2.13B | $16.02M |
Sector | Health | Utilities |
52-Week High | $20.38 | $6.66 |
52-Week Low | $7.60 | $0.75 |
Enterprise Value | $2.20B | $22.18M |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
FLUX trades at $0.8199, down 8.75% over 24 hours. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $6.67 million in 2025 with a negative net margin of 12.48%, while revenue declined to $51 million in 2026. Recent developments include the launch of SkyEMS 3.0 AI software and new executive appointments aimed at growth.
Outlook remains speculative with unanimous analyst buy ratings contrasting weak profitability. Key opportunities lie in software innovation and market expansion, but risks include persistent losses, revenue volatility, and intense clean energy competition. The stock's appeal hinges on execution turning losses to profits.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →